Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.55 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | PLAU | P00749 | 5/20 | 0.46 |
| ▸ | HPN | P05981 | 5/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200245 | 0.98 | MMP2 (0.57) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL200247 | 0.98 | MMP2 (0.57) | MMP2MMP9PLAUHPNITGB3 | |
| Hydrochloric Acid SCHEMBL920895 | 0.96 | MMP2 (0.56) | MMP2MMP9PLAUHPNITGB3 | |
| Hydrochloric Acid SCHEMBL11406948 | 0.96 | MMP2 (0.56) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL1305743 | 0.87 | MMP2 (0.56) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL1305745 | 0.87 | MMP2 (0.56) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL5490595 | 0.85 | PLAU (0.45) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL28509074 | 0.85 | MMP2 (0.60) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL20008635 | 0.85 | MMP9 (0.67) | MMP2MMP9ITGB3ITGA2BSLC1A3 | |
| SCHEMBL28212986 | 0.85 | MMP9 (0.67) | MMP2MMP9ITGB3ITGA2BSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191206-A1 | SERUM FREE MEDIA FOR SUSPENSION CULTURE OF MAMMALIAN LIVESTOCK PLURIPOTENT STEM CELLS | ACCELLTA LTD. (IL) | 2024-06-13 | — | — | US | disclosed |
| EP-4352204-A1 | SERUM FREE MEDIA FOR SUSPENSION CULTURE OF MAMMALIAN LIVESTOCK PLURIPOTENT STEM CELLS | Accellta Ltd. (IL) | 2024-04-17 | — | — | EP | disclosed |
| CN-117795057-A | Serum-free medium for suspension culture of pluripotent stem cells of mammalian livestock | 艾策尔塔公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240085429-A1 | ALTERING PROTEIN FUNCTION BY PHARMACOLOGICAL TARGETING OF MEMBRANE DOMAINS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3506915-B1 | HUMAN BLOOD-DERIVED PRODUCTS HAVING DECREASED FIBRINOLYTIC ACTIVITY AND USES THEREOF IN HEMOSTATIC DISORDERS | PLAS FREE LTD (IL) | 2024-03-06 | — | — | EP | disclosed |
| US-20230000911-A1 | HUMAN BLOOD-DERIVED PRODUCTS HAVING DECREASED FIBRINOLYTIC ACTIVITY AND USES THEREOF IN HEMOSTATIC DISORDERS | PLAS-FREE LTD (IL) | 2023-01-05 | — | — | US | disclosed |
| WO-2022259254-A1 | SERUM FREE MEDIA FOR SUSPENSION CULTURE OF MAMMALIAN LIVESTOCK PLURIPOTENT STEM CELLS | ACCELLTA LTD. (IL) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021033722-A1 | METHOD FOR PRODUCING HABITUATED CELLS, METHOD FOR MANAGING HABITUATED CELLS, DEVICE FOR MANAGING HABITUATED CELLS, AND COMPUTER PROGRAM | 昭和電工マテリアルズ株式会社 | 2021-02-25 | — | — | WO | disclosed |
| US-20190284526-A1 | CULTURE MEDIA FOR CULTURING PLURIPOTENT STEM CELLS IN SUSPENSION | ACCELLTA LTD. (IL) | 2019-09-19 | — | — | US | disclosed |
| EP-3506915-A2 | HUMAN BLOOD-DERIVED PRODUCTS HAVING DECREASED FIBRINOLYTIC ACTIVITY AND USES THEREOF IN HEMOSTATIC DISORDERS | Plas-Free Ltd (IL) | 2019-07-10 | — | — | EP | disclosed |
| US-20190192564-A1 | HUMAN BLOOD-DERIVED PRODUCTS HAVING DECREASED FIBRINOLYTIC ACTIVITY AND USES THEREOF IN HEMOSTATIC DISORDERS | PLAS-FREE LTD (IL) | 2019-06-27 | — | — | US | disclosed |
| EP-3487987-A1 | CULTURE MEDIA FOR CULTURING PLURIPOTENT STEM CELLS IN SUSPENSION | Accellta Ltd. (IL) | 2019-05-29 | — | — | EP | disclosed |
| CN-109789162-A | Human blood product-derived with reduced fibrinolytic and its purposes in disorder of hemostasis | 普拉斯富瑞有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109661462-A | For cultivating the culture medium of multipotent stem cells under suspension | 阿塞尔塔有限公司 | 2019-04-19 | — | — | CN | disclosed |
| WO-2018042438-A2 | HUMAN BLOOD-DERIVED PRODUCTS HAVING DECREASED FIBRINOLYTIC ACTIVITY AND USES THEREOF IN HEMOSTATIC DISORDERS | PLAS-FREE LTD (IL) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018015954-A9 | CULTURE MEDIA FOR CULTURING PLURIPOTENT STEM CELLS IN SUSPENSION | ACCELLTA LTD. (IL) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018015954-A1 | CULTURE MEDIA FOR CULTURING PLURIPOTENT STEM CELLS IN SUSPENSION | ACCELLTA LTD. (IL) | 2018-01-25 | — | — | WO | disclosed |
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | NIH - DEITR | 2015-04-09 | — | — | US | disclosed |
| WO-2013177492-A2 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | PNLIP, LIPE, LIPC | MMP2 1245/4885MMP9 1299/4885PLAU 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.